Nilotinib Teva

Nilotinib, the active ingredient in Nilotinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for chronic myeloid leukemia (CML) that is resistant to or intolerant of prior therapy, providing a targeted option for patients who have limited alternatives.

GNH USA supplies Nilotinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality and regulatory compliance across global markets. The company follows stringent quality standards and provides reliable logistics for timely delivery.

Nilotinib is a tyrosine kinase inhibitor used in the management of chronic myeloid leukemia, a myeloproliferative disorder driven by BCR‑ABL fusion protein activity.

- Chronic myeloid leukemia (CML) resistant or intolerant to prior therapy: provides disease control by targeting BCR‑ABL mutations that are not responsive to earlier treatments.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools. - Rash: skin redness or itching. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - QT interval prolongation: may affect heart rhythm. - Pancreatitis: inflammation of the pancreas. - Severe neutropenia: markedly low white blood cell count.

Before initiating therapy, clinicians should consider the following precautions: - Cardiac monitoring: assess baseline ECG and correct electrolyte abnormalities. - Hematologic monitoring: perform regular complete blood counts. - Hepatic function: check liver enzymes periodically. - Pregnancy risk: avoid use in pregnancy; category D. - Drug‑specific warnings: counsel patients on signs of QT prolongation. - Store at room temperature: keep in the original container, protect from moisture and light.

Nilotinib may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nilotinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: can lower absorption; separate dosing by at least 2 hours. - Certain statins (e.g., simvastatin, lovastatin): may increase statin levels; consider dose adjustment or alternative lipid‑lowering therapy.